Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mito-HF: Bioarginine C in Heart Failure
NCT06044194Phase 3Recruiting
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoint: Viability of mitochondria isolated from peripheral blood of mononucleate cells (PBMC) at 3 months. Started Mar 2023; status: recruiting.
Beyond the preview
Go deeper on NCT06044194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044194.